Stock Price Movements, Share Repurchase Programs, and Financial Results - Research Report on Jazz Pharmaceuticals, Novo Nordisk,

  Stock Price Movements, Share Repurchase Programs, and Financial Results -
  Research Report on Jazz Pharmaceuticals, Novo Nordisk, Teleflex, DENTSPLY
                           International, and Fonar

PR Newswire

NEW YORK, November 20, 2013

NEW YORK, November 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Jazz
Pharmaceuticals plc (NASDAQ: JAZZ), Novo Nordisk A/S (ADR) (NYSE: NVO),
Teleflex Incorporated (NYSE: TFX), DENTSPLY International Inc. (NASDAQ: XRAY),
and Fonar Corporation (NASDAQ: FONR). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Jazz Pharmaceuticals plc Research Report

On November 15, 2013, Jazz Pharmaceuticals plc's (Jazz Pharmaceuticals) stock
declined 0.28%, ending the day at $108.39. Over the previous three trading
sessions, shares of Jazz Pharmaceuticals gained 7.12%, outperforming the
Nasdaq Composite which gained 1.68% during the same period. The Full Research
Report on Jazz Pharmaceuticals plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ

Novo Nordisk A/S (ADR) Research Report

On November 11, 2013, Novo Nordisk A/S (ADR) (Novo Nordisk) announced that on
October 31, 2013, the Company initiated a share repurchase program pursuant to
the provisions of the European Commission's regulation no. 2273/2003 of
December 22, 2003, also known as the Safe Harbor rules. Novo Nordisk informed
that this program is part of the overall share repurchase program of up to
(Danish Krone) DKK14.0 billion to be executed during a 12-month period
starting January 31, 2013. The Full Research Report on Novo Nordisk A/S (ADR)
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fee1_NVO

Teleflex Incorporated Research Report

On November 12, 2013, Teleflex Incorporated (Teleflex) announced that it was
recently awarded a new agreement from Novation for its complete line of Arrow
Intra-Aortic Balloon Catheters and Pumps. Teleflex further reported that the
agreement, effective January 1, 2014, will provide more than 65,000 members by
Novation with a variety of offerings from Teleflex, including the AutoCAT 2
WAVE Intra-Aortic Balloon Pump with the proprietary wave algorithm which
detects the aortic valve closure point for each beat as it occurs. Teleflex
informed that this technology enables accurate timing based on the individual
characteristics of each heartbeat instantly, even during severe arrhythmia.
Howard Miller, President, Cardiac Care Division of Teleflex, said, "We are
proud to partner with Novation through the new agreement which provides
hospital members the advanced Arrow® Intra-Aortic Balloon Technology from
Teleflex for treating patients with severe cardiac events." The Full Research
Report on Teleflex Incorporated - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9c7d_TFX

DENTSPLY International Inc. Research Report

On November 15, 2013, DENTSPLY International Inc.'s (DENTSPLY International)
stock rose 0.14%, ending the day at $48.62. Over the previous three trading
sessions, shares of DENTSPLY International gained 1.29% compared to the Nasdaq
Composite which gained 1.68% during the same period. The Full Research Report
on DENTSPLY International Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/6b01_XRAY

Fonar Corporation Research Report

On November 15, 2013, Fonar Corporation (Fonar) reported its Q1 FY 2014
financial results (period ended September 30, 2013). The Company's total net
revenues increased 77% YoY to $16.8 million during the quarter. Net income
available to common stockholders was $2.3 million or $0.37 per diluted share
in Q1 FY 2014 compared to net income available to common stockholders of $1.4
million or $0.22 per diluted share in Q1 FY 2013. Raymond V. Damadian M.D.,
President and Chairman of Fonar Corporation, said, "We had understood that the
acquisition of HDM would be a significant source of profitability. This has
been the case and the Company's diluted earnings per share available for the
common stockholder for the 1st quarter of Fiscal 2014 increased 68% to $0.37
when compared to one year earlier. There are more reasons why this acquisition
makes a lot of sense. By combining the resources of HMCA and HDM, we will
enjoy the benefits of economies of scale, shared administrative and technical
expertise and capabilities, and joint marketing strategies. HMCA's 11
STAND-UP® MRIs together with HDM's 12 form a network of 23 FONAR
weight-bearing MRI scanners, the largest in the world as compared to the
conventional essentially weightless MRI." The Full Research Report on Fonar
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73cc_FONR

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)